Tiziana Life Sciences Ltd (TLSA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tiziana Life Sciences Ltd (TLSA) has a cash flow conversion efficiency ratio of -115.846x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.02 Million) by net assets ($52.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Tiziana Life Sciences Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Tiziana Life Sciences Ltd - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Tiziana Life Sciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tiziana Life Sciences Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tiziana Life Sciences Ltd ranked by their cash flow conversion efficiency. See Tiziana Life Sciences Ltd cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bonny Worldwide Ltd
TW:8467
|
-0.005x |
|
Parkit Enterprise Inc
V:PKT
|
0.019x |
|
AB VILKUSKIU PIEN.EO 029
F:UDW
|
0.050x |
|
Rawlplug S.A.
WAR:RWL
|
0.070x |
|
MEDIFAST INC
NYSE:MED
|
0.009x |
|
Companhia Estadual de Distribuição de Energia Elétrica
SA:CEED3
|
-0.016x |
|
Inclusio Sca
BR:INCLU
|
0.002x |
|
Smartbroker Holding AG
XETRA:SB1
|
0.097x |
Annual Cash Flow Conversion Efficiency for Tiziana Life Sciences Ltd (1998–2025)
The table below shows the annual cash flow conversion efficiency of Tiziana Life Sciences Ltd from 1998 to 2025. View Tiziana Life Sciences Ltd (TLSA) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $52.00K | $-12.85 Million | -247.058x | -79644.98% |
| 2024-12-31 | $3.94 Million | $-1.22 Million | -0.310x | +86.19% |
| 2023-12-31 | $5.54 Million | $-12.42 Million | -2.244x | -174.65% |
| 2022-12-31 | $19.57 Million | $-15.99 Million | -0.817x | -109.07% |
| 2021-12-31 | $41.28 Million | $-16.13 Million | -0.391x | -178.41% |
| 2020-12-31 | $62.39 Million | $-8.76 Million | -0.140x | -111.09% |
| 2019-12-31 | $-4.18 Million | $-5.29 Million | 1.266x | +114.26% |
| 2018-12-31 | $409.01K | $-3.63 Million | -8.875x | -362.93% |
| 2017-12-31 | $-1.68 Million | $-5.68 Million | 3.375x | +299.20% |
| 2016-12-31 | $3.31 Million | $-5.62 Million | -1.694x | -152.95% |
| 2015-12-31 | $8.50 Million | $-5.70 Million | -0.670x | +48.54% |
| 2014-12-31 | $1.78 Million | $-2.31 Million | -1.302x | -295.67% |
| 2013-12-31 | $-146.00K | $-97.13K | 0.665x | -88.32% |
| 2012-12-31 | $-40.00K | $-227.89K | 5.697x | +439.16% |
| 2011-12-31 | $525.00K | $-881.91K | -1.680x | -148.77% |
| 2010-12-31 | $604.00K | $-407.86K | -0.675x | -52.98% |
| 2009-12-31 | $1.21 Million | $-535.42K | -0.441x | +38.37% |
| 2008-12-31 | $1.34 Million | $-959.80K | -0.716x | +18.70% |
| 2007-12-31 | $2.44 Million | $-2.15 Million | -0.881x | -8.97% |
| 2006-12-31 | $2.43 Million | $-1.96 Million | -0.809x | -92.97% |
| 2005-12-31 | $2.83 Million | $-1.18 Million | -0.419x | +13.69% |
| 2004-12-31 | $3.54 Million | $-1.72 Million | -0.485x | +3.58% |
| 2003-12-31 | $3.03 Million | $-1.52 Million | -0.503x | +29.33% |
| 2002-12-31 | $2.21 Million | $-1.57 Million | -0.712x | +14.07% |
| 2001-12-31 | $2.96 Million | $-2.46 Million | -0.829x | -51.50% |
| 2000-12-31 | $4.01 Million | $-2.19 Million | -0.547x | -106.04% |
| 1999-12-31 | $1.98 Million | $-527.00K | -0.266x | -93.05% |
| 1998-12-31 | $2.25 Million | $-310.00K | -0.138x | -- |
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes… Read more